Blood stem cell collections after mobilization with combination chemotherapy containing ifosfamide followed by G-CSF in multiple myeloma by Straka, C. et al.
Oncology 2003;65(suppl 2):94–98
DOI: 10.1159/000073368
Blood Stem Cell Collections after Mobilization
with Combination Chemotherapy Containing
Ifosfamide Followed by G-CSF in Multiple
Myeloma
C. Strakaa H. Hebartb S. Adler-Reichela N. Werdinga B. Emmericha
H. Einseleb
aMedizinische Klinik-Innenstadt, Klinikum der Universität München, München und bMedizinische Klinik,
Klinikum der Universität Tübingen, Tübingen, Deutschland
Dr. Christian Straka, Stammzelltransplantation
Medizinische Klinik-Innenstadt, Klinikum der Universität München
Ziemssenstrasse 1, DE–80336 München (Germany)
Tel. +49 89 5160 2278, Fax +49 89 5160 4424
E-Mail cstraka@medinn.med.uni-muenchen.de
ABC
Fax + 41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
© 2003 S. Karger AG, Basel
0030–2414/03/0656–0094$19.50/0
Accessible online at:
www.karger.com/ocl
Key Words
Peripheral blood stem cells W Mobilization W Stem cell
collection W Multiple myeloma W G-CSF W Ifosfamide
Abstract
High-dose chemotherapy with autologous peripheral
blood stem cell transplantation is the standard treatment
of patients with multiple myeloma today. In this study we
used a combination mobilizing chemotherapy contain-
ing ifosfamide with G-CSF before stem cell collection.
The chemotherapy regimen consisted of ifosfamide
(2,500 mg/m2 days 1–3), epirubicin (100 mg/m2 day 1)
and etoposide (150 mg/m2 days 1–3) followed by G-CSF
(5 Ìg/kg from day 5). In 30 younger patients (median age
51 years; range 41–60 years) who received the IEV regi-
men in 100% dosage, a median of 11.15 ! 106 CD34+
cells/kg (range 0–44.60 ! 106 CD34+ cells/kg) was col-
lected. In 22 elder patients (median age 64 years; range
59–72 years) similar collection results were obtained
with a median of 10.82 ! 106 CD34+ cells/kg (range 0.99–
42.22 ! 106 CD34+ cells/kg) after the IEV regimen in 75%
dosage. The pretreatment chemotherapy cycles before
mobilization were fewer in elder patients with a median
of 0 cycles (range 0–7 cycles) compared with younger
patients with a median of 4 cycles (range 0–7 cycles).
These collection results were favorable and allowed to
support a tandem transplantation procedure in younger
and elder patients in 97 and 95%, respectively. In the
majority of patients, the hematological toxicity of IEV
was of WHO grade 3/4. The extramedullary toxicity was
mild to moderate and there were only few cases (5–10%)
of relevant nephrotoxicity or neurotoxicity associated
with the application of ifosfamide.
Copyright © 2003 S. Karger AG, Basel
Introduction
High-dose therapy followed by autologous peripheral
blood stem cell transplantation was found to be superior
to conventional chemotherapy in patients with multiple
myeloma [1–4]. Gianni et al. [5, 6] pioneered the use of
chemotherapy with hematopoietic growth factors to mo-
bilize and collect peripheral blood stem cells in lymphoma
and multiple myeloma. The standard mobilization regi-
men in multiple myeloma in the 1990s was high-dose
cyclophosphamide (4–7 g/m2) followed by GM-CSF or G-
CSF [7–9]. Clinical studies which aim at improving the
yield of stem cell collections with combination chemo-
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therapy as compared to single-agent cyclophosphamide
are ongoing. To optimize stem cell collections is impor-
tant because nowadays frequently tandem transplanta-
tion programs [2] are offered to patients with multiple
myeloma which were found to improve survival over sin-
gle high-dose chemotherapy in a prospective randomized
trial [10].
The median age at diagnosis in patients with multiple
myeloma is between 65 and 70 years. Today, high-dose
chemotherapy with melphalan and autologous blood stem
cell transplantation is increasingly being offered to elder
patients. Age-adapted dosing of melphalan in high-dose
protocols appears to be favorable [11, 12]. The outcome of
elder patients with multiple myeloma treated with high-
dose chemotherapy does not seem to be inferior to the
results obtained for younger patients [11, 13, 14].
In this investigation we used a combination of ifosfam-
ide (2,500 mg/m2 days 1–3), epirubicin (100 mg/m2 day 1)
and etoposide (150 mg/m2 days 1–3) followed by G-CSF
(5 Ìg/kg) for stem cell mobilization and collection in mul-
tiple myeloma. There is experience with this combination
for stem cell mobilization in lymphoma patients [15]. The
combination of ifosfamide, epirubicin and etoposide with
G-CSF was found to produce better collection results than
high-dose cyclophosphamide alone with G-CSF. Here we
report our experience with this mobilization regimen in
multiple myeloma. For patients above the age of 60, gen-
erally a dose reduction to 75% was carried out.
Patients and Methods
Patients
Two cohorts of consecutive multiple myeloma patients were
treated in age-adapted high-dose chemotherapy protocols of the Ger-
man Study Group on multiple myeloma (DSMM) at two centers. The
characteristics of the patients are shown in table 1.
IEV Chemotherapy and G-CSF
The IEV chemotherapy regimen was given for blood stem cell
mobilization. The IEV regimen consists of ifosfamide 2,500 mg/m2,
i.v., days 1–3, epirubicin 100 mg/m2, i.v., day 1, and etoposide
100 mg/m2, i.v., days 1–3, followed by G-CSF (filgrastim; Amgen,
Thousand Oaks, Calif., USA) at a dose of 5 Ìg/kg, s.c., daily from day
5 until the completion of blood stem cell harvesting. The younger
patients up to an age of 60 years received the IEV regimen in a 100%
dosage. Apart from individual dose reductions, patients with an age
of 60 years or above generally received the IEV regimen in a 75%
dosage.
Blood Stem Cell Collection and Cryopreservation
Autologous blood stem cells were harvested when the post-nadir,
G-CSF-stimulated leukocyte count rose up to 5,000–10,000/Ìl or
above using a Cobe Spectra (Cobe, Heimstetten, Germany) or an
Table 1. Patient characteristics
Younger patients Elder patients
Number 30 22
Age
Median 51 64
Range 41–60 59–72
Gender
Male 17 (57%) 11 (50%)
Female 13 (43%) 11 (50%)
Salmon-Durie stage
I 1 (3%) –
II 12 (40%) 5 (23%)
III 17 (57%) 17 (77%)
M-protein type
G 20 (67%) 15 (68%)
A 2 (7%) 2 (9%)
M 1 (3%) –
Bence-Jones 5 (17%) 5 (23%)
Anaplastic 1 (3%) –
Non-secretory 1 (3%) –
Creatinine
12 mg% 2 (7%) 2 (9%)
!2 mg% 28 (93%) 20 (91%)
ß2-Microglobulin, mg/l
Median 3.3 3.4
Range 1.0–11.5 1.9–9.2
CRP, mg/dl
Median 0.4 0.5
Range 0.1–11.0 0.1–4.6
AS104 (Fresenius, St. Wendel, Germany) cell separator and standard
programs. Approximately 10 l of blood were processed at a flow rate
of 50 ml/min. The harvested blood stem cells were mixed with an
equal volume of a freezing solution which was prepared with 5%
HSA and 100% DMSO (Cryoserv, Tera Pharmaceuticals, Midvale,
Utah, USA) (4:1). The final DMSO concentration was 10%. After
computerized controlled-rate freezing, the bags containing the blood
stem cells were stored in the vapor phase of liquid nitrogen.
CD34+ Cell Enumeration of Autologous Blood Stem Cells
The determination of CD34+ cells was carried out according to
the guidelines of ISHAGE [16] using a FACScan (BD, Mountain
View, Calif., USA) or an EPICS XL-MCL (Electronics, Miami, Fla.,
USA) flow cytometer equipped with an argon laser. Whole blood was
incubated for 30 min at 4°C in the dark with the PE-conjugated
monoclonal anti-CD34 antibody and the FITC-conjugated mono-
clonal anti-CD45 antibody followed by a wash and red blood cell
lysis (BD). Seventy-five thousand cells were analyzed. To exclude cell
debris, platelets, remaining red cells and all CD45-negative cells, a
forward scatter versus CD45 fluorescence dot plot was used. The
double-positive CD34+/CD45+ cell population was then defined and
backgated for low CD45 expression and low side scatter properties.
The percentage of the so defined CD34+ cells was multiplied with the
total nucleated cell content of the apheresis product to obtain the
absolute number of CD34+ cells harvested. The nucleated cell con-
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Table 2. Treatment characteristics and collection results
Younger patients Elder patients
Number 30 22
Chemotherapy cycles
Median 4 0
Range 0–7 0–7
Radiation therapy
Yes 13 (43%) 6 (28%)
No 17 (57%) 16 (72%)
IEV dose
50% – 1 (5%)
66% 1 (3%) –
75% 2 (7%) 21 (95%)
100% 27 (90%) –
Leukaphereses
Median 2 2
Range 0–5 1–6
CD34+ cells collected, ! 106/kg
Median 11.15 10.82
Range 0–44.60 0.99–42.22
Proportion with 14 ! 106/kg
CD34+ cells 97% 95%
tent was determined by automated cell counting using a Coulter
STKS (Coulter, Miami, Fla., USA). The anti-CD34 antibody
(HPCA-2), the anti-CD45 antibody (2D1) and the isotype controls
used were from BD.
High-Dose Treatment Protocols
The IEV regimen was part of a sequential treatment plan. Up to
an age of 60 years, patients first received induction chemotherapy
with 3–4 cycles of ID or VAD. Then the IEV regimen was applied.
After adequate stem cell collections, the patients proceeded either to
tandem high-dose melphalan at a dose of 200 mg/m2 or to a single
high-dose treatment with an intensified conditioning regimen con-
sisting of total marrow irradiation with shielding of the liver and the
lungs (3 ! 2 ! 1.5 Gy), busulfan 9 mg/kg, and cyclophosphamide
2 ! 60 mg/kg. At an age of 60 years and above, the patients were
either treated with dexamethasone alone or with 3–4 cycles of ID or
VAD before IEV. When stem cell collections were adequate, the
patients proceeded to tandem high-dose melphalan at a dose of 100–
140 mg/m2.
Results
Younger (median age 51 years; range 41–60 years) and
elder (median age 64 years; range 59–72 years) multiple
myeloma patients were treated with a combination of
ifosfamide, epirubicin and etoposide (IEV) followed by
G-CSF before blood stem cell collections. The patient
characteristics for both cohorts of patients are shown in
Table 3. Toxicity of IEV chemotherapy
Younger patients Elder patients
Number 30 22
Hematological
WHO grade 1 1 (3%) 1 (5%)
WHO grade 2 7 (23%) 1 (5%)
WHO grade 3 5 (17%) 7 (31%)
WHO grade 4 17 (57%) 11 (50%)
Undetermined – 2 (9%)
Infection
WHO grade 1/2 3 (10%) 2 (9%)
WHO grade 3 0 1 (5%)
Gastrointestinal
WHO grade 3/4 3 (10%) 4 (18%)
Neurological
WHO grade 1/2 1 (3%) 2 (9%)
WHO grade 3/4 1 (3%) 0
Nephrological
WHO grade 1/2 1 (3%) 1 (5%)
WHO grade 3/4 1 (3%) 1 (5%)
table 1. All patients were in stage II or III of their disease
with the exception of 1 stage I patient. Less than 10% in
both cohorts had a creatinine level 12 mg%. The levels of
ß2-microglobulin and C-reactive protein were also similar
in both groups. Pretreatment with chemotherapy, how-
ever, had been carried out with more cycles in the younger
patient group (table 2). Dexamethasone alone was the
treatment before stem cell mobilization in 45% of elder
patients but only in 3% of younger patients. Pretreatment
with radiotherapy again was similar for both groups.
The younger patients usually were to receive a 100%
dosage of the IEV regimen, what was actually carried out
in 90% of younger patients. In 2 patients, the dose was
reduced to 75% because of renal insufficiency and in 1
patient IEV could not be completed because of neurologi-
cal toxicity of ifosfamide, resulting in a reduced dose of
ifosfamide and etoposide of 66%. The elder patients
usually were to receive a 75% dosage of IEV, what was
possible in 95% of patients. In 1 patient the dose was fur-
ther reduced to 50% because of renal insufficiency.
The number of leukapheresis harvests carried out in
both patient groups was similar with a median of two
leukaphereses (table 2). Also the number of CD34+ cells
collected was similar between younger patients with a
median of 11.15 ! 106 CD34+ cells/kg and the elder
patient cohort with a median of 10.82 ! 106 CD34+ cells/
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kg. In 1 younger patient, stem cell collection was not pos-
sible because of chemorefractory disease and persistence
of hyperviscosity after IEV. Since the patients were candi-
dates for a tandem high-dose chemotherapy with mel-
phalan, 4 ! 106 CD34+ cells/kg were required for both
transplants. This was achieved in the younger patients in
97% and in the elder patients in 95%.
The toxicity of IEV in the younger and elder patients
(with dose reduced IEV) was similar (table 3). The majori-
ty of patients developed WHO grade 3/4 hematological
toxicity. There was one WHO grade 3 infectious compli-
cation in an elder patient. The gastrointestinal toxicity
WHO grade 3/4 was somewhat higher in elder patients
with 18% versus 10% in the younger patients. An ifosfa-
mide-related encephalopathy which required the applica-
tion of methylene blue occurred in 1 of the younger (3%)
and in 1 of the elder (5%) patients. There were singular
cases of a WHO grade 3/4 nephrotoxicity among younger
and elder patients. No treatment-related mortality was
observed in both groups.
Discussion
Effective blood stem cell collections could be carried
out after combination chemotherapy with ifosfamide,
epirubicin and etoposide followed by G-CSF in patients
with multiple myeloma. Both in younger and elder pa-
tients, similar collection results with a median of around
10 ! 106 CD34+ cells/kg after a median of two leukapher-
eses were obtained. In the younger patients, the IEV regi-
men was applied in a 100% dosage. The younger patients
had received more previous chemotherapy with a median
of 4 cycles. In elder patients, the IEV dosage was generally
reduced to 75% because of concerns regarding toxicity.
Elder patients had received less previous chemotherapy
with a median of 0 cycles due to a strategy of early stem
cell harvesting. In patients with no conventional chemo-
therapy before stem cell harvesting, dexamethasone alone
had been given for symptom control and stability of dis-
ease during the harvesting period. These results demon-
strate that a strategy of early stem cell collection in elder
patients with dose-reduced mobilizing chemotherapy can
result in a similar high collection efficiency than in youn-
ger patients being treated according to the conventional
strategy of stem cell mobilization after 3–4 cycles of
induction chemotherapy.
The stem collections in our patients aimed at a mini-
mum dose of 4 ! 106 CD34+ cells/kg to support a tandem
transplantation procedure. This target dose was achieved
in 695% of both younger and elder patients. When com-
pared to the collection results obtained after high-dose
cyclophosphamide (4–7 g/m2) with G-CSF in multiple
myeloma, collection results appear to be superior with
IEV [17, 18]. Indeed, in lymphoma patients, it was found
that a mobilization with IEV and G-CSF gave superior
collection results than high-dose cyclophosphamide with
G-CSF [15]. In a study in lymphoma and multiple myelo-
ma, high-dose ifosfamide alone with GM-CSF was com-
pared with high-dose cyclophosphamide followed by GM-
CSF regarding stem cell collection results [19]. Blood stem
cell collections yielded slightly less CD34+ cells after high-
dose ifosfamide but without statistical significance. The
toxicity profile, however, after high-dose ifosfamide was
favorable. This shows that ifosfamide can make an impor-
tant contribution to stem cell mobilization within combi-
nation chemotherapy regimes.
In order to avoid the substantial hematological and
non-hematological toxicity after high-dose cyclophospha-
mide, lower doses of cyclophosphamide (1.5 g/m2) were
investigated for stem cell mobilization in lymphoma and
multiple myeloma [20]. A target dose of 2.5 ! 106 CD34+
cells/kg to support a single transplant, however, could be
harvested in only 64% of patients. This shows that reduc-
ing myelosuppression also reduces the following stem cell
mobilization and collection during the post-nadir hema-
tological rebound.
Blood stem cell mobilization with G-CSF alone at a
higher dose of 10 Ìg/kg or above has the advantage of a
low toxicity and the days of collection can be precisely
planned. Yet, the collection results frequently are inferior
to what can be obtained with the combination of chemo-
therapy and hematopoietic growth factors for mobiliza-
tion [21, 22]. This, however, does not necessarily lead to
an inferior engraftment [22].
Several studies have shown that pretreatment with
melphalan decreases stem cell mobilization and collection
results significantly [9, 17]. In our study, only 1 younger
patient (3%) and 1 elder patient (5%) had received pre-
vious melphalan treatment.
In order to ameliorate toxicity, ifosfamide was given
over several hours and a glucose infusion was co-adminis-
tered. In around 10% of cases, neurotoxicity developed in
our patients which presented as an encephalopathy and
required a therapy with methylene blue in 1 younger (3%)
and 1 elder (5%) patient. Severe WHO grade 3/4 nephro-
toxicity occurred in ^5% of cases. The majority of youn-
ger and elder patients receiving IEV with G-CSF devel-
oped a hematological toxicity WHO grade 3/4. It there-
fore is required to perform regular blood tests and a clini-
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cal evaluation of the patient, for example three times
weekly after discharge of the patient from the hospital fol-
lowing the administration of IEV chemotherapy. Platelet
transfusions may be necessary in some patients. There is a
potential risk of neutropenic fever around day 10 and a
potential risk of bacterial sepsis has to be taken into con-
sideration. Altogether, the toxicity profile appears to be
adequate when put into relation with the high efficiency
of this regimen in stem cell mobilization and collection.
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